Vesugen

What is it?

Vesugen is a Khavinson tripeptide (Lys-Glu-Asp / KED) targeting vascular endothelium — claimed to modulate gene expression for angiogenesis, endothelial repair, and vascular tone. It’s part of the vascular/cardiovascular corner of the Khavinson short-peptide bioregulator family, alongside Cardiogen. No structured study list existed on the source directory at capture time (2026-06-07), but a later verification pass (2026-06-22) surfaced real primary literature — see below.

What does it do in my body?

Claimed mechanism: like the rest of the Khavinson family, Vesugen is proposed to cross cell and nuclear membranes, bind DNA, and modulate transcription in a tissue-specific way — here, in vascular endothelial cells, promoting angiogenesis and endothelial repair.

How can it help me?

• Where the science stands: Directory listed “Anecdotal” (0 studies) at capture time; two primary papers since surfaced — one (mouse Alzheimer’s model), one

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No serious AEs are documented for Vesugen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Vesugen’s thin published record makes it an easier target for mislabeling since there’s little independent literature to check a seller’s claims against. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Vesugen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Vesugen holds no clinical-use approval anywhere.

Part 1 — How to reconstitute it

What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.

The exact bacteriostatic-water volume and resulting concentration for Vesugen are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.

How to mix it

• Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
• Swirl gently to dissolve. Never shake — shaking can damage the peptide.
• Store the reconstituted vial refrigerated and out of light.
• Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.

Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.

Part 2 — Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.

Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Vesugen in humans (the only human data is an observational cohort study, not a dose-finding trial). What exists is the Khavinson-school cycle pattern shared across the family:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year.
• Dose: as a synthetic short tripeptide, community subcutaneous dosing converges around ~100–200 mcg/day over the cycle; no Vesugen-specific human dose-finding data exists to confirm this. The Khavinson mouse study used 400 μg/kg IP daily — not directly convertible to a human SubQ protocol.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Treat every number above as community/Russian-protocol convergence, not validated human dosing.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.

What should I avoid combining — and what's synergistic?

Vesugen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

How can I buy this?